FDA grants approval for Amylyx’s Relyvrio to treat ALS
Pharmaceutical Technology
OCTOBER 1, 2022
Diarrhoea, nausea, upper respiratory tract infection and abdominal pain were reported to be the most common adverse events linked to Relyvrio. Additionally, treatment with Relyvrio substantially reduced physical function loss in ALS patients.
Let's personalize your content